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AbstrAct
Patients with chronic heart failure (CHF) have 
symptoms and concerns which are inadequately 
addressed. Patient-reported outcome 
measures (PROMs) can potentially improve the 
identification and management of advanced 
symptoms and palliative concerns. However, 
these have not been used in CHF.
Objectives To examine the feasibility and 
acceptability of using a PROM—the Integrated 
Palliative care Outcome Scale (IPOS)—together 
with heart failure nurse education and training 
to improve the identification and management 
of symptoms and concerns among patients with 
CHF.
Methods A parallel, mixed methods design 
with an embedded qualitative component was 
used to examine the feasibility of recruitment, 
retention, intervention adherence/compliance 
and follow-up assessment completion (symptom 
burden, quality of life, psychological well-being). 
Patient and nurse qualitative semistructured 
interviews explored intervention and study 
design feasibility and its acceptability.
results Conversion to consent was 46.9% 
(372 screened, 81 approached, 38 recruited). 
66% of patient participants completed the IPOS; 
6% of IPOS questionnaire items were missing 
(non-response). Over two-thirds (65.6%) of 
these missing items related to three patients. 
No item was consistently missing; appetite was 
the most frequent missing item (1.4%). 92% of 
participants who completed the IPOS completed 
all follow-up assessments (1–2 days, 1–2 weeks 
and 4–6 weeks post-IPOS completion) with no 
missing data. The a priori feasibility objectives 
were met. Patients and nurses reported the 
intervention and study design feasible and 
acceptable.
conclusions A palliative-specific PROM-based 
intervention is feasible and acceptable to both 
patients with CHF and nurses in nurse-led 
disease management clinics for the purposes of 
both clinical care and research.
IntrOductIOn
Chronic heart failure (CHF) affects 
1%–2% of the adult population and is 
characterised by high symptom burden 
and volatility with up to a 50% sudden 
death risk.1 The Innovative Care for 
Chronic Conditions (ICCC) framework 
recommends, for chronic conditions 
including CHF, that patients become 
active, prepared and informed rather 
than passive healthcare recipients.2 Policy 
makers advise a patient-centred approach 
for CHF involving a holistic patients’ 
needs assessment and care goal prefer-
ence identification3–5; aspects of care 
sharing a similar philosophy with palli-
ative care.6 Patient-centred care can act 
to facilitate the integration of a palliative 
care approach into CHF management for 
patients with deteriorating health and 
high mortality risk.6
Patient-centred CHF interventions 
reduce symptom burden and increase 
patient engagement, by enabling patients 
to identify their needs, communicate 
these needs and collaborate with health-
care professionals to address these needs 
according to patients’ preferences.6 This 
process is difficult to evaluate.7 Tools to 
help patients with CHF to do this are 
lacking.
Patient-reported outcome measures 
(PROMs) facilitate patient-centred care8 
by providing a subjective assessment 
of patients’ perceptions of their own 
health status.9 PROMs identify patients’ 
unmet needs by helping patients commu-
nicate their problems to healthcare 
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professionals.8 Given the paucity of CHF palliative 
care needs assessment research, palliative-specific 
PROM use to identify patients’ advanced symptoms 
and palliative concerns is timely. This intervention 
involves the Integrated Palliative care Outcome Scale 
(IPOS), a PROM designed to capture palliative symp-
toms and concerns,10 with integrated healthcare profes-
sional education and training. The intervention’s aim 
is to improve identification and management of CHF 
advanced symptoms and palliative concerns.
MethOds
design
As recommended by the Medical Research Coun-
cil’s (MRC) framework for the development and 
evaluation of complex interventions,11 a feasibility 
and acceptability study was undertaken to test the 
following methodological components: recruitment, 
retention, intervention compliance/adherence, inter-
vention acceptability, follow-up assessment comple-
tion and possible effect size to inform selected 
follow-up measures appropriateness. This study 
used a parallel, mixed methods embedded research 
design,12 comprising a pre–post uncontrolled quanti-
tative component and embedded qualitative compo-
nent. This design was chosen to inform the feasibility 
and acceptability objectives for a future pilot cluster 
randomised controlled trial (RCT).
setting and sample
Patients attending nurse-led CHF disease manage-
ment clinics in two national tertiary referral centres 
in Dublin, Ireland were eligible if they had CHF; 
New York Heart Association (NYHA) functional class 
III–IV, with systolic dysfunction and left ventricular 
ejection fraction (HFrEF) of <40% or heart failure 
symptoms and either midrange systolic function 
(HFmrEF): 40%–49% or preserved systolic function 
(HFpEF) ≥50%; fluency and literacy in English; suffi-
cient cognitive function to complete the question-
naires and were ≥18 years of age. Cognitive function 
was assessed clinically by the nurses. Patient inclusion 
criteria were developed in conjunction with the heart 
failure nurses involved in intervention delivery, were 
based on the 2012 European Society of Cardiology’s 
CHF definition1 13 and included HFpEF.1 The 2016 
European Society of Cardiology’s CHF definition14 
does now include HFpEF in its definition. Recruited 
patients’  caregivers  were  eligible  if  they  were  ≥18 
years of age, provided unpaid care, and had capacity 
to complete the questionnaires. The caregivers were 
identified by the patient.
recruitment
Nurses involved in the nurse-led clinics were invited 
to participate in the patient recruitment, the interven-
tion and qualitative semistructured interviews postin-
tervention. They identified and approached eligible 
clinic patients with study information and obtained 
permission for the researcher to contact them, who 
then consented interested patients. Where patients 
with an identified caregiver agreed, caregivers were 
approached and consented.
ethics
Ethics approval was obtained from Research Ethics 
Committees at hospital sites (Ref: 13/70 and Ref: 
1/378/1579) and King’s College London (Ref: 
BDM/13/14–25). Written informed consent was 
obtained from patients, caregivers and participating 
nurses. A Project Advisory Group comprising expert 
clinicians, researchers and a service user was estab-
lished to discuss study findings and to inform the 
evaluation.
sample size
While a sample size was not calculated (outcomes of 
interest were intervention and study design feasibility 
and acceptability), a minimum of 20 patients was 
required; the number considered adequate to identify 
95% of IPOS usability problems.15 16 This intervention 
was delivered at a service level rather than at a patient 
level. In a full-scale study, service level randomisation 
as part of a cluster trial would be appropriate. For this 
study, involving only two sites, service level randomi-
sation was therefore not possible, so the feasibility of 
randomisation was not tested.
Intervention
The IPOS (see online supplementary appendix 1) with 
integrated heart failure nurse education and training 
was delivered alongside best standard care (box). 
(Intervention description follows template for inter-
vention description and replication guidelines.)17 Once 
nurses at each site had received patient-centred care 
education and IPOS training, they gave recruited 
patients the IPOS to complete at the subsequent clinic 
visit. The IPOS has 10 questions with two open ques-
tions covering patients’ main concerns and symp-
toms, respectively, and a five-point Likert scale (0–4) 
accompanying common symptoms, patient and family 
distress, existential well-being, sharing feelings with 
family, information available and practical concerns.10
baseline and follow-up measures
The intervention aimed to reduce symptom burden 
and improve quality of life6; this informed follow-up 
measure selection. The feasibility and acceptability 
of the selected study measures were assessed to 
determine those most appropriate for a definitive 
trial. The primary follow-up measure was symptom 
burden, measured using the Edmonton Symptom 
Assessment System-revised (ESAS-r) which has 
been used successfully in CHF.21 Each of its nine 
symptoms is ranked on a scale of 0–10: 0 (absent 
symptom) and 10 (worst possible severity) with a 
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global score range of 0–90. Secondary follow-up 
measures included: the Kansas City Cardiomyop-
athy Questionnaire (KCCQ),22 the Patient Health 
Questionnaire-8 (PHQ-8)23 and a quality of life 
visual analogue scale. The KCCQ is a 23-item ques-
tionnaire quantifying functional limitations, symp-
toms, social limitations and quality of life in the 
preceding 2 weeks and is sensitive to patients with 
CHF health status changes.22 Scores range from 0 to 
100; higher scores indicate a better health status. An 
intraindividual  change of ≥5 points  is  considered 
clinically significant.24 The PHQ-8 is an eight-item 
questionnaire with good psychometric properties 
in the CHF population.23 Scores range from 0 to 
24;  a  score  of ≥10  indicates  clinically  significant 
depression requiring clinical review.25 Patients’ 
perceived quality of life was assessed using a visual 
analogue scale; patients rate quality of life ‘today’ 
and ‘the week before using the IPOS’ on a scale of 
1–7: 1 (very poor) and 7 (excellent). Informal care-
giver baseline and follow-up measures involved the 
Zarit Caregiver Burden Interview-12 (ZBI-12),26 
where each of the 12 statements is ranked on a 
Likert scale (0–5): 0 (never) and 5 (nearly always) 
with a global score of 0–48 measuring caregivers’ 
perceptions of care demands.26 It has been used 
with caregivers of patients with CHF.27 Quantita-
tive data were entered into SPSS V.22.
Patients completed questionnaires by telephone 
(mean time 14 min) at baseline in a 2-week period 
preceding IPOS completion, then 1–2 days, 1–2 
weeks and 4–6 weeks after IPOS completion. These 
Box Description of the intervention
Integrated Palliative care Outcome Scale (IPOS) with integrated heart failure nurse (HFN) education and training
Aims and rationale
The intervention aimed to provide a subjective assessment of patients’ palliative symptoms and concerns to improve their 
identification and management within the heart failure nursing clinical review. HFN education on patient-centred care and IPOS 
training aimed to facilitate optimal IPOS use.8 Following Knowles andragogy principles,18 HFNs were involved in the education 
and training development. Case studies using IPOS underwent external expert review to ensure clinical accuracy for patients with 
chronic heart failure (CHF). The IPOS has been designed to capture patients’ palliative symptoms and concerns, which are well 
documented in CHF.19 The IPOS parent patient-reported outcome measure (PROM), the Palliative Care Outcome Scale has been 
used in CHF.20 This intervention was developed using the Medical Research Council guidance and informed through a systematic 
review6 using the best available evidence4 and appropriate theory.8
 
Content
The intervention involved two components; Part one was HFN education on patient-centred care and IPOS training; Part two 
was the subsequent use of the IPOS with recruited patients in the clinic. The education and training followed a heterogeneous 
pedagogical approach with five components: (1) patient-centred care overview, (2) rationale for PROM use, (3) rationale for IPOS, 
(4) IPOS case studies and (5) practicalities of IPOS use in the clinic. The IPOS has 10 questions with two open questions covering 
patients’ main concerns and symptoms, respectively, and a five-point Likert scale (0–4) accompanying common symptoms, 
patient and family distress, existential well-being, sharing feelings with family, information available and practical concerns.10 
After delivery of the education and training to the HFNs, recruited patients completed the IPOS at their next clinic visit. HFNs then 
reviewed each patient with the completed IPOS. HFNs were advised to address individual items with scores ≥3; use their clinical 
discretion for individual scores ≤2; and assess any problems included in the open questions. No clinical guidelines were provided 
as HFNs were expected to use their clinical expertise in assessment and management of these symptoms/concerns, referring to 
other specialist services as they deemed appropriate. As the IPOS was used once with each patient, an overall IPOS score was not 
used.
 
Personnel
Provider: The primary researcher delivered the 1-hour patient-centred care education and IPOS training at each study site once 
to the HFNs. The HFNs provided recruited patients with the IPOS.
Supervision: The primary researcher was on site when recruited patients attended the nurse-led CHF disease management 
clinic, prompted the HFNs to give patients the IPOS and to remind patients to complete both sides and reminded HFNs to store 
completed IPOS in the provided repository.
 
Format
Setting: Patients completed the IPOS while waiting to be reviewed at the nurse-led CHF disease management clinic.
Schedule and duration: Twenty-five patients completed the IPOS. On arrival to the clinic, HFNs provided patients with a paper 
copy of the IPOS on a clipboard with a pen.
 
Delivery
Delivery methods: The HFNs were advised where patients requested assistance to complete the IPOS not to paraphrase, not 
to give their own explanations of the questions, to adhere to the questionnaire text and not to prompt patients with potential 
answers. Only HFNs who had attended the module subsequently were involved in IPOS patient delivery and clinical use.
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time intervals were selected to enable identification 
of the optimum time for follow-up measure collec-
tion in a future trial. Where longer intervals have 
been used, the potential effect was thought to have 
been missed.28 Patients requiring assistance with 
questionnaire completion was used as a feasibility 
marker.
Feasibility and acceptability
A priori criteria for study feasibility and acceptability 
were as follows.
 ► Recruitment  and  retention:  consent  rate  of  ≥40%  of 
patients approached about the study29; recruitment 
of ≥20 patients15 and retention of ≥65%, given the high 
attrition and mortality rate in this population.6 16
 ► Follow-up data feasibility and accepta-
bility: ≥90% completion  of  each  of  the  questionnaires 
and items.30 31
 ► Intervention  feasibility  and  acceptability:  ≥90%  IPOS 
completion by retained patients30 31 and 100% interven-
tion protocol adherence.
data collection and management
Patients for the qualitative interviews were purpo-
sively identified to include a broad range of char-
acteristics relevant to the study in terms of age, 
gender, NYHA class and heart failure type (HFpEF 
or HFmrEF/HFrEF). Face-to-face interviews were 
audiorecorded, transcribed by an independent tran-
scription company, checked for accuracy, anonymised 
and imported into MAXQDA32 software to facilitate 
analysis.
data analysis
Study methodology feasibility was examined using the 
following quantitative data: recruitment, retention, 
follow-up measure response rates, missing follow-up 
measure data and missing IPOS data. Quantitative anal-
ysis was descriptive statistics and standardised effect 
size calculation using Cohen’s d where d=0.2 is a small 
effect size, d=0.5 is medium and d=0.8 is large.33 We 
applied an analytical framework developed by Bugge 
et al34 to systematically categorise and explore issues in 
feasibility studies based on 14 potential methodolog-
ical issues identified by Shanyinde et al.35 Study design 
and intervention feasibility and acceptability were 
explored using patient and nurse qualitative semistruc-
tured interviews conducted by PMK with a sample size 
of 18 patients. The potential mechanism of action of 
the intervention was also examined. These findings are 
reported separately.36 Qualitative data were analysed 
using framework analysis.37A priori codes were drawn 
from the interview topic guide (see online supple-
mentary appendix 2) study objectives and feasibility 
guidelines.38 PMK was the primary coder. CES coded 
interviews; consensus on themes and key findings were 
reached through discussion.
results
Recruitment and baseline data collection ran from 
September 2014 to February 2015. Final qualitative 
interviews were completed in June 2015. The Bugge 
et al34 analytical framework was applied to the study 
findings (table 1).
recruitment and retention
Three hundred and seventy-two patients were screened, 
81 patients were approached, 38 were recruited and 25 
completed the intervention. The proportion of patients 
approached who consented (conversion to consent) 
was above the target set (46.9%).34 Figure 1 shows the 
modified Consolidated Standards of Reporting Trials 
flow diagram of recruited patients.39 Fifteen caregivers 
were recruited with 10 caregivers retained. Five care-
givers were lost due to patient attrition because if a 
patient withdrew from the study, their caregiver was 
also withdrawn.
Table 2 shows patients’ characteristics. Participants 
were predominantly male (56.5%), mean age 75.4±9.0 
years of age, NYHA III (65.2%), HFrEF (52.2%) and 
mean Charlson comorbidity index of 4.0±1.2.40
Intervention adherence/compliance
All eligible nurses participated in education and 
training and were actively involved in intervention 
delivery. Intervention adherence was achieved; all 25 
retained patients were given the IPOS. Patient compli-
ance was achieved; all 25 patients completed the IPOS 
with a small proportion (29, 6.4%) of total missing 
items. Nineteen of these 29 missing items were from 
three patients. The most common missing item was 
appetite, omitted by four patients. Eight patients 
(32%) required assistance with IPOS completion: 
three from a relative/friend and five from the nurse. 
Symptoms mentioned in the open questions included 
pruritus, insomnia, immobility, leg swelling and cough.
baseline and follow-up data assessment
Of 25 patients who completed the IPOS, two with-
drew after IPOS completion as they were admitted 
to hospital and were too unwell to continue. The 
remaining 23 participated in three subsequent tele-
phone data collection points and completed all the 
questionnaires: there were no missing data for these 
patients (100% data completion rate). Table 3 shows 
the standardised effect sizes at the three time points 
post-IPOS completion. As the number of measures is 
large and the sample size is small, these analyses are 
useful for descriptive purposes only.
Qualitative findings
Eighteen patients and all four nurses were interviewed 
postintervention. Interviews ranged from 21 to 44 min 
(mean 32 min) in length. Patients found the IPOS 
accessible and appropriate. The intervention was both 
feasible and acceptable to the nurses as was the study 
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Table 1 Summary of the findings against 14 methodological issues for feasibility research
Methodological issues Findings Evidence
1. Did the feasibility study allow a sample size 
calculation for the main trial?
No No, as the effect size on the chosen primary 
outcome was too small.
2. What factors influenced eligibility and what 
proportion of those approached were eligible?
A proportion of patients were too unwell or too 
distressed to be approached
Only eligible patients were approached
3. Was recruitment successful? Recruitment was difficult, issues with 
comprehensive identification of patients
NYHA assignment differed between the two sites
4. Did eligible participants consent? Good conversion to consent Thirty-eight recruited out of 81 eligible, consent 
rate of 46.9%
5. Were participants successfully randomised and 
did randomisation yield equality in groups?
Not investigated in this study Not investigated in this study
6. Were blinding procedures adequate? Not investigated in this study Not investigated in this study
7. Did participants adhere to the intervention? Good adherence to IPOS completion Thirty-eight patients recruited, 25 completed IPOS, 
13 LTFU
8. Was the intervention acceptable to the 
participants?
Minimal amount of missing IPOS data (6.4%); 
acceptability explored in qualitative interviews
Patients and nurses found the intervention 
acceptable and feasible
9. Was it possible to calculate intervention costs 
and duration?
Cost of the intervention was not assessed Costs for resource utilisation were assessed for 
participant service use (not reported here)
10. Were outcome assessments completed? Where participants persisted, there was no 
missing data as outcome data were collected on 
the telephone
There was no missing data for baseline and 
outcome measures
11. Were outcomes measured those that were the 
most appropriate outcomes?
Outcomes consistent with the theory underpinning 
the intervention were used11
See summary of outcome data in table 3
12. Was retention to the study good? Once recruited, retention was good Response rates:
Time point one questionnaire (24/25)
Time point two questionnaire (23/25)
Time point three questionnaire (23/25)
13. Were the logistics of running a multicentre trial 
assessed?
Recruitment was slow at one site until challenges 
were identified and addressed. The presence of the 
researcher at each site positively influenced the 
logistical running of study
Site 1: 14 patients, eight caregivers
Site 2: nine patients, two caregivers
14. Did all components of the protocol work 
together?
Components worked well together There were no difficulties identified in the 
various processes and the researcher’s ability to 
implement them. Patients once recruited were 
readily identified.
Methodological issues based on Shaniyinde et al35 and Bugge et al.34
IPOS, Integrated Palliative care Outcome Scale; LFTU, lost to follow-up; NYHA, New York Heart Association.
design. The full qualitative findings are presented in 
the online supplementary appendix 3.
dIscussIOn
This study demonstrates that a palliative-specific 
PROM-based intervention (based on IPOS) with 
patients with CHF in nurse-led CHF disease manage-
ment clinics is feasible and acceptable to patients 
and staff for research use. The methods used were 
successful as demonstrated by high compliance and 
protocol adherence, good patient and caregiver reten-
tion and little missing data, demonstrating interven-
tion feasibility and acceptability. The intervention 
integrated well into the busy nurse-led clinics, comple-
menting existing practice without requiring additional 
resources. Study implementation strategies were effec-
tive, including: reminders to ensure recruited patients 
received the IPOS, researcher’s presence at each study 
site at IPOS introduction to address any problems and 
staff engagement. This study’s findings will inform a 
future pilot cluster RCT as they illustrate the effective 
facilitators and barriers to IPOS use in this population 
in nurse-led clinics. Service-level randomisation feasi-
bility needs further testing.
Recruitment challenges were expected in this CHF 
population41 but were compounded by intersite 
NYHA classification differences necessitating a longer 
recruitment period. Recruitment initially was diffi-
cult at one site with small numbers of eligible patients 
approached and a high refusal rate which was due 
to study site differences in NYHA class assignment. 
NYHA reliability problems are well recognised.42 To 
address this difference, the study site recruiting lower 
numbers included patients currently assigned NYHA 
class II who had recently been NYHA class III/IV. This 
is discussed in depth elsewhere.43 IPOS use in a clinical 
healthcare environment may result in a higher partic-
ipation rate than in the research setting; the latter can 
preclude patients from participating. Retention was 
good from the selected population; 25 of 38 recruited 
patients (65%)16 received the intervention and 23 of 
these (92%) completed all follow-up data collection 
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Figure 1 Modified Consolidated Standards of Reporting Trials flow diagram. IPOS, Integrated Palliative care Outcome Scale.
points, suggesting that this study design was feasible in 
this population. Patient attrition is a recognised chal-
lenge in advanced disease studies and may even affirm 
inclusion of the correct population.44
One of the main themes in the qualitative data was 
IPOS accessibility. Patients described the IPOS as user 
friendly and having easy readability, including two 
patients with self-acknowledged suboptimal literacy. 
Poor literacy is a recognised barrier to PROM acces-
sibility in chronic obstructive pulmonary disease,45 
which is likely to have resonance with the CHF popu-
lation. Health numeracy deteriorates with increasing 
age and cognitive impairment, so being accessible in 
this way is an important attribute for the IPOS. Cogni-
tive impairment, which was not formally assessed here, 
may present in up to 75% of older patients with CHF 
and is independently associated with CHF.46 The IPOS 
did not lengthen clinical reviews but some patients 
required more time for IPOS completion. Conducting 
PROM research in an older population with comor-
bidities including visual impairment and arthritis can 
make form filling more challenging; these patients 
required assistance with IPOS completion. None of 
the patients found the IPOS burdensome. The IPOS is 
a generic rather than disease-specific PROM and was 
designed to assess for palliative symptoms and other 
concerns.10 Those with advanced progressive disease 
including CHF and cancer experience many common 
symptoms,47 so it is unsurprising that patients and 
nurses described the IPOS as appropriate and relevant 
to their experience of the illness burden in CHF.
Patients with CHF adjust their lifestyle to reduce 
symptom exacerbation, therefore reporting less 
symptom severity.48 Time pressures on clinical inter-
actions compound this deficit and the reluctance of 
patients to vocalise their distress.49 Systematic symptom 
assessment such as the IPOS, identifies significantly 
more symptoms than patients volunteer.50 Partici-
pants found this intervention to be an accessible and 
quick way to assess for palliative symptoms and other 
concerns. Patients’ perceived quality of life relates to 
how much a disease and its treatment prevent them 
from achieving their goals.51 Arguably, in the setting 
of chronic progressive disease, where interventions 
offered are non-curative and not life prolonging, the 
overall aim should be quality of life improvement.51
The ESAS, KCCQ and PHQ-8 were observed as being 
feasible with no missing data for retained patients. Tele-
phone quantitative interviews were arranged to suit 
patients’ schedules; this data collection method may 
partly address the missing data challenges in advanced 
disease studies.44 PHQ-8 telephone administration has 
been validated.52 ESAS and KCCQ telephone admin-
istration have been conducted elsewhere.53 The small 
participant number precludes definite conclusions 
regarding the most appropriate primary outcome 
measure. While it is not advisable to look for an effect 
in a feasibility study as it is inadequately powered,54 
our findings nevertheless provide some information to 
inform the selection of primary outcome measures and 
timing for a future definitive trial. It was hypothesised 
that this intervention would enable patients to identify 
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Table 2 Demographics and clinical characteristics
All 
participants 
(n=25)
Male, n (%) 14 (56)
Age, years (mean±SD) 75.7±9.2
Married, n (%) 15 (60)
Education, n (%)
  <Secondary School 12 (48)
  Some/completed Secondary School 9 (36)
  Some/completed university 4 (16)
Body mass index, kg/m2 (mean±SD) 27.1±4.8
NYHA functional class, n (%)
  II 8 (32)
  III 16 (64)
  IV 1 (4)
Ejection fraction, % (mean±SD) 39.2±14.8
Type of ejection fraction, n (%)
  HFrEF 10 (40)
  HFmrEF and HRpEF 15 (60)
Systolic blood pressure (mm Hg) (mean±SD) 118.6±19.1
Diastolic blood pressure (mm Hg) (mean±SD) 66.5±9.7
Creatinine (µmol/L) (mean±SD) 129.7±46.8
eGFR (mean±SD) 59.9±29.3
Diabetes mellitus, type 2, n (%) 8 (32)
Chronic obstructive pulmonary disease, n (%) 8 (32)
Hypertension, n (%) 14 (56)
Ischaemic heart disease, n (%) 17 (68)
Myocardial infarction 12 (48)
CABG 12 (48)
PCI 9 (36)
Major depression, n (%) 5 (20)
Charlson comorbidity index (mean±SD) 4.0±1.2
Smoking (including previous smoker), n (%) 18 (72)
Medication use, n (%)
  ACE-i/angiotensin receptor blockers 20 (80)
  Beta-blockers 25 (100)
  Digoxin/amiodarone/ivabradine 13 (52)
  Antidepressants and/or anxiolytics 7 (38)
  Pain medications 10 (40)
CRT-D (ICD), n (%) 12 (48)
ACE-i, ACE inhibitor; CABG, coronary artery bypass grafting; CRT-D, 
cardiac resynchronisation therapy defibrillator; eGFR, estimated 
glomerular filtration rate; HFrEF, heart failure reduced ejection fraction; 
HFpEF, heart failure preserved ejection fraction; HRmrEF, heart failure 
mid-range ejection fraction; ICD, implantable cardiac defibrillator; PCI, 
percutaneous coronary intervention.
their symptoms and concerns in order that the nurses 
act on these, potentially resulting in improved quality 
of life. Symptom burden (ESAS-r) identified only a 
small positive effect immediately postintervention 
which was not sustained. This intervention may have 
more short-term effects which could be investigated 
in a larger definitive study. Since this was a feasibility 
study that was not adequately powered to detect the 
effect of the intervention, we nevertheless, conducted 
qualitative interviews to explore the potential mech-
anism of action of the intervention. This is reported 
separately.36 Patients with CHF need a holistic 
patient-centred approach28 to better understand, iden-
tify and address their symptoms and concerns.48 The 
challenges experienced by heart failure professionals 
in providing holistic care are recognised.55 The educa-
tion and training aimed to support the nurses in how 
to interpret and act on IPOS feedback and on patient 
empowerment but did not provide management guide-
lines. The nurses’ actions in response to IPOS feedback 
were left to their clinical discretion. There is no clear 
evidence as to which approach is preferable.56 One 
option in a future study may be to identify available 
services, for example, a physiotherapy-led programme 
on breathlessness management and incorporate prede-
termined IPOS criteria into the education and training 
to prompt referrals. It is here that the value of a mixed 
methods approach is highlighted. This approach that 
follows the MRC guidance11 and provides greater 
insight into the feasibility, acceptability and imple-
mentation of this complex intervention and pre–post 
design.57
limitations
This study only tests the methodology of a pre–post 
design in urban teaching hospital sites. Therefore, study 
numbers were too small to detect differences between 
the two study site populations. Patients recruited to 
this study accessed nurse-led disease management 
clinics designed to improve patient clinical outcomes. 
Therefore, they do not represent the wider CHF 
population. A pilot cluster RCT would be required to 
provide a better estimate of the intraclass correlation 
coefficient to estimate the sample size for a definitive 
trial. The researcher (PMK) was involved in all study 
stages: study design, implementation and subsequent 
evaluation. Since the number of participants was rela-
tively small, true anonymous quantitative evaluation 
was difficult. This may have introduced bias partic-
ularly in assessing acceptability and feasibility of the 
education and training. However, the nurses correctly 
interpreted the IPOS and understood the rationale 
for its use where this was explored in the qualitative 
interviews; these data findings could potentially be 
used as a measure of the effectiveness of the education 
and training. The researcher’s role in facilitating study 
implementation must not be overlooked. The imple-
mentation literature58 outlines how to investigate 
researchers’ roles in study implementation. However, 
this was not investigated here. While the IPOS was not 
modified for heart failure, the open questions allowed 
patients to highlight additional concerns.
cOnclusIOn
This study identifies that this palliative-specific PROM 
intervention using the IPOS is feasible and acceptable 
for patients with CHF and as it is not burdensome 
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Table 3 Patient and caregiver follow-up measures
Measure
Baseline (time point 0) 
mean score (SD) n=25
Mean standardised effect size (d) from baseline
Time point 1
1–2 days post-IPOS (mean 
(¯x, SD)) n=24
Time point 2
1–2 weeks post-
IPOS (mean, SD) n=23
Time point 3
4–6 weeks post-
IPOS (mean, SD) n=23
ESAS-r 24.72 (16.73) 0.05 −0.31 −0.11
(¯x 23.9, SD 15.8) (¯x 29.9, SD 19.6) (¯x 26.5, SD 15.0)
KCCQ overall clinical 
summary score
61.4 (25.4) 0.18 −0.23 −0.02
(¯x 62.6, SD 25.4) (¯x 56.7, SD 17.2) (¯x 59.8, SD 15.2)
KCCQ overall summary score 56.6 (16.7) −0.06 −0.09 −0.02
(¯x 56.3, SD 14.7) (¯x 54.4, SD 15.3) (¯x 55.6, SD 16.7)
KCCQ self-efficacy score 82.1 (18.0) 0.29 0.44 0.44
(¯x 88.0, SD 11.6) (¯x 89.7, SD 9.7) (¯x 89.7, SD13.4)
PHQ-8 3.20 (4.21) 0.01 0.10 0.10
x¯ 3.0, SD 3.6) (¯x 2.8, SD 4.4) (¯x 2.8, SD 3.9)
Quality of life (VAS) 5.15 (1.25) 0.22 0.16 0.34
(¯x 5.5, SD 1.4) (¯x 5.4, SD 1.4) (¯x 5.6, SD 1.0)
ZBI-12 21.90 (6.92) – – −0.56
(¯x 25.8, SD 3.2)
ESAS, Edmonton symptom assessment system; IPOS, Integrated Palliative care Outcome Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; PHQ-8: 
Patient-Health Questionnaire; VAS: Visual Analogue Scale; ZBI-12: Zarit Caregiver Burden Interview-12.
to patients. This intervention integrated well into 
nurse-led CHF disease management clinics, did not 
require additional resource use and did not impede 
clinical practice. Using the MRC guidance, our find-
ings add to the evidence base and support further 
development and evaluation of these types of inter-
ventions, which this study demonstrates are feasible 
for research.
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